Therapeutic advancements are taking place at a steady pace for oncology treatments, and ensuring these advancements reach eligible patients in a timely and equitable manner across countries is critical. The availability and use of these therapies vary across different countries, however, and can lead to inequities in patient outcomes.

This event hosted by the IQVIA Institute with a multi-stakeholder panel of experts discussed:

• Patient access variations in rate and time to availability of precision oncology therapies in Algeria, Egypt, Saudi Arabia, South Africa, and the UAE
• Factors driving geographical access hurdles to oncology therapies
• Current policy gaps, ongoing initiatives, and potential solutions to increase oncology therapy availability to patients
• The path ahead for increased patient access to oncology therapies

It built on key findings from the recent IQVIA Institute report: Oncology Therapy Access in the Era of Personalized Medicine: Trends in regulatory approval and reimbursement for select countries in the Middle East and Africa.

Moderator:

Murray Aitken
Executive Director, The IQVIA Institute for Human Data Science

Speakers:

Her Excellency Dr. Mouza bin Hamrour Al Ameri
Breast Surgeon, Chief of Breast Care Center, Tawam Hospital/ SEHA

Dr. Khaled Abdel-Aziz Kamal
Consultant of Clinical Oncology at Ain Shams University, Executive Director of the Presidential Initiative for Cancer Early Detection and Management

Dr. Mohammad Al Nahedh
Director, Pharmaceutical Care Division, Clinical Pharmacy Consultant, hematology/Oncology, King Faisal Specialist Hospital and Research Center

Dr. Jacques Snyman
Director and owner of Forte Research Co. (Pty) Ltd, Consultant for Pharmacology Research and HTA